Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin.

Garcia-Rodriguez C, Geren IN, Lou J, Conrad F, Forsyth C, Wen W, Chakraborti S, Zao H, Manzanarez G, Smith TJ, Brown J, Tepp WH, Liu N, Wijesuriya S, Tomic MT, Johnson EA, Smith LA, Marks JD.

Protein Eng Des Sel. 2011 Mar;24(3):321-31. doi: 10.1093/protein/gzq111. Epub 2010 Dec 13.

2.

Mode of action of botulinum neurotoxins: current vaccination strategies and molecular immune recognition.

Aoki KR, Smith LA, Atassi MZ.

Crit Rev Immunol. 2010;30(2):167-87. Review.

PMID:
20370628
3.

Botulinum neurotoxins and botulism: a novel therapeutic approach.

Thanongsaksrikul J, Chaicumpa W.

Toxins (Basel). 2011 May;3(5):469-88. doi: 10.3390/toxins3050469. Epub 2011 May 13. Review.

4.

Progress in cell based assays for botulinum neurotoxin detection.

Pellett S.

Curr Top Microbiol Immunol. 2013;364:257-85. doi: 10.1007/978-3-642-33570-9_12. Review.

5.

Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins.

Atassi MZ, Oshima M.

Crit Rev Immunol. 1999;19(3):219-60. Review.

PMID:
10422600
6.

Unique ganglioside binding by botulinum neurotoxins C and D-SA.

Kroken AR, Karalewitz AP, Fu Z, Baldwin MR, Kim JJ, Barbieri JT.

FEBS J. 2011 Dec;278(23):4486-96. doi: 10.1111/j.1742-4658.2011.08166.x. Epub 2011 May 31. Review.

7.

The European AntibotABE Framework Program and Its Update: Development of Innovative Botulinum Antibodies.

Rasetti-Escargueil C, Avril A, Miethe S, Mazuet C, Derman Y, Selby K, Thullier P, Pelat T, Urbain R, Fontayne A, Korkeala H, Sesardic D, Hust M, Popoff MR.

Toxins (Basel). 2017 Oct 2;9(10). pii: E309. doi: 10.3390/toxins9100309. Review.

8.

Vaccines against Botulism.

Sundeen G, Barbieri JT.

Toxins (Basel). 2017 Sep 2;9(9). pii: E268. doi: 10.3390/toxins9090268. Review.

Supplemental Content

Support Center